Mason Michael 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
Mason Michael
SVP, CFO & Treasurer
Transactions
- Sale
Common Stock
2023-03-01$3.03/sh−11,205$33,942→ 245,361 total - Award
Common Stock
2023-02-28+95,000→ 256,566 total
Footnotes (2)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
- [F2]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.